- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04486937
SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation (mCRPC)
Sc10914 Monotherapy for Metastatic Castration Resistant Prostate Cancer Patients With Germ and / or Somatic BRCA Mutation: a Single Arm, Multicenter Clinical Tria
Study Overview
Status
Intervention / Treatment
Detailed Description
The subjects oral administration sc10914 tablets 400mg on an empty stomach, three times a day, for 28 consecutive days as a treatment cycle, until disease progression (PD) (according to Recist1.1 and the adjusted PCWG3 standard, the subjects met the imaging [CT / MRI / bone scan] PD standard) or the toxicity was intolerable.
The study is divided into two stages: in the first stage,enrolled 36 patients whose response can be evaluated, if there are at least 7 cases of objective remission (CR or PR), the second stage is allowed, otherwise the study will be stopped; in the second stage, the number of subjects whose response can be evaluated is planned to continue to be enrolled to 70 cases(stage 1 and stage 2).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Wanwan Ji
- Phone Number: 18852605644
- Email: jiwanwan@sh-qingfeng.net
Study Contact Backup
- Name: Yuping Zhang
- Phone Number: 18010196244
- Email: zhangyuping@sh-qingfeng.net
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signing informed consent voluntarily;
- Prostate cancer confirmed by histology or cytology;
- Metastatic lesions proved by imaging (CT / MRI / bone scan);
- At least one measurable lesion in accordance with recist1.1;
- deleterious or suspected deleterious germline and/or somatic BRCA-mutated (g/sBRCAm)
- ECOG≤2;
- The expected survival time was more than 3 months;
- Serum testosterone levels ≤ 50 ng/dL (≤ 1.75 nmol/L) at screening.
- Subjects without prior surgical castration must be currently taking and willing to continue luteinizing hormone-releasing hormone (LHRH) analog (agonist or antagonist) therapy throughout the duration of study treatment.
9.Subjects must have progressed on prior NHA (e.g. abiraterone acetate and/or enzalutamide) for the treatment of mCRPC. 10.Subjects must have progressed on prior chemotherapy with docetaxel for the treatment of mCRPC.
Exclusion Criteria:
- Any previous treatment with PARP inhibitor
- Concomitant use of known strong CYP3A inhibitors or moderate CYP3A inhibitors. The required washout period prior to starting olaparib is 2 weeks or 5 half-life.
- Subjects with known brain metastases.
- Major surgery within 2 weeks of starting study treatment and subjects must have recovered from any effects of any major surgery
- Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with Absorption, distribution, metabolism and excretion of the study
- Immunocompromised subjects, e.g., subjects who are known to be serologically positive for human immunodeficiency virus (HIV)
- Subjects with a known hypersensitivity to SC10914 or any of the excipients of the product
- Subjects with known active hepatitis (i.e. Hepatitis B or C)
Subjects with not enough organ functional reserve at baseline, which met at least one of the following criteria:
- ANC<1.5×109/L;
- PLT<100×109/L;
- Hb<100g/L;
- TBIL>1.5×ULN;
- ALT、AST>2.5×ULN unless liver metastases are present in which case they must be > 5×ULN;
- Cr >1.5×ULN。
Subjects who have impaired cardiac function or clinically significant cardiac diseases, including any of the following:
- Baseline QT interval corrected for heart rate (HR) using Fridericia's formula >500 msec or congenital long QT syndrome;
- Left ventricular ejection fraction (LVEF) <50% assessed by echocardiogram;
- Other clinically significant heart disease such as congestive heart failure NYHA Class IV and requiring heart transplant
- Severe bone injury caused by tumor bone metastases as judged by the researchers, including severe bone pain due to poor control, pathological fracture of important parts or spinal cord compression occurred or expected to occur in the near future in the last 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SC10914
400mg TID,oral admination on an fasting state
|
S410914 tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objective response rate (ORR)
Time Frame: up to 100 weeks (estimated)
|
assessed by the independent imaging assessment committee (recist1.1)
|
up to 100 weeks (estimated)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: up to 100 weeks (estimated)
|
up to 100 weeks (estimated)
|
|
Disease control rate (DCR), duration of response (DOR), time to tumor progression (TTP)
Time Frame: up to 100 weeks (estimated)
|
evaluated according to recist1.1 and adjusted pcwg3 criteria
|
up to 100 weeks (estimated)
|
overall survival (OS)
Time Frame: up to 100 weeks (estimated)
|
evaluated according to recist1.1 and adjusted pcwg3 criteria
|
up to 100 weeks (estimated)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- QF-SC10914-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration Resistant Prostate Cancer
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Rohan GarjeJanssen Scientific Affairs, LLCNot yet recruitingCastration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
Clinical Trials on S410914 tablet
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
Sequel Pharmaceuticals, IncTerminatedAtrial Fibrillation
-
Stallergenes GreerCompleted
-
TakedaWithdrawn
-
Harmony Biosciences, LLCRecruiting
-
Xgene Pharmaceutical GroupRecruiting
-
Abbisko Therapeutics Co, LtdCompleted
-
Haisco Pharmaceutical Group Co., Ltd.Haisco Pharmaceutical(Australia) Pty Ltd.Completed
-
China Resources Sanjiu Medical & Pharmaceutical...Not yet recruitingAnkylosing SpondylitisChina